On Nov. 25, 2022, Pink Sheet published an article titled “Clinical Trial Diversity Would Benefit from Regulatory, Financial Incentives, Experts Say,” and the piece referenced remarks Partner Winston Kirton gave at a recent Food and Drug Law Institute conference.
Kirton told conference attendees that improving trial diversity from the beginning of drug development through commercialization is not simply a social issue. “It will provide better data to regulators,” he said. Furthermore, while it would be nice if greater diversity happened on its own, “We live in a society and in a country where incentives matter.”
Read the article (subscription required).